Increased thrombin-activatable fibrinolysis inhibitor antigen levels as a clue for prothrombotic state in polycystic ovary syndrome

Karakurt F., Gumus I. I., Bavbek N., Kargili A., Koca C., Selcoki Y., ...Daha Fazla

Gynecological Endocrinology, cilt.24, sa.9, ss.491-497, 2008 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 24 Sayı: 9
  • Basım Tarihi: 2008
  • Doi Numarası: 10.1080/09513590802291824
  • Dergi Adı: Gynecological Endocrinology
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.491-497
  • Anahtar Kelimeler: Thrombin-activatable fibrinolysis inhibitor, polycystic ovary syndrome, cardiovascular disease, Diane-35, fibrinolysis, CORONARY-ARTERY-DISEASE, TERM-FOLLOW-UP, PRACTICE RESEARCH DATABASE, ISCHEMIC-HEART-DISEASE, VENOUS THROMBOEMBOLISM, INSULIN-RESISTANCE, CARDIOVASCULAR-DISEASE, MYOCARDIAL-INFARCTION, ORAL-CONTRACEPTIVES, CYPROTERONE-ACETATE
  • Lokman Hekim Üniversitesi Adresli: Hayır

Özet

Objectives. Our study was undertaken to evaluate the levels of thrombin-activatable fibrinolysis inhibitor (TAFI) antigen and also its relationship with other hemostasis markers in a group of patients affected with polycystic ovary syndrome (PCOS)-under Diane-35 (ethinyl estradiol 0.035 mg/cyproterone acetate 2 mg) treatment or not-as compared with a group of healthy controls. Methods. Forty-two women with PCOS and 30 age-matched healthy controls were involved in the study. Group A were on Diane-35 for at least 6 months; group B did not take any drug; group C served as a control group. Results. TAFI antigen levels of groups A and B were significantly higher than in controls, but no difference was observed between them. All of the other coagulation and fibrinolysis parameters (including prothrombin time, activated partial thromboplastin time, fibrinogen and D-dimer) were comparable between the three groups. Conclusion. The evidence presented herein suggests that women with PCOS have impaired fibrinolysis, as reflected by increased TAFI. This impairment can contribute to the risk of cardiovascular disease in PCOS. Elucidation of the modifiable mechanisms in PCOS can represent an opportunity for preventive therapy of the cardiovascular risks associated with PCOS. © 2008 Informa Healthcare USA, Inc.